Merck (NYSE: MRK) reported sales of $16 billion for the third quarter of 2023, up 7% from the same period a year ago. GAAP net income increased 46% to $4.7 billion, or $1.86 per share, compared to last year. Adjusted EPS rose 15% to $2.13. For the full year of 2023, the company expects worldwide […]
Merck (NYSE: MRK) reported sales of $16 billion for the third quarter of 2023, up 7% from the same period a year ago. GAAP net income increased 46% to $4.7 billion, or $1.86 per share, compared to last year. Adjusted EPS rose 15% to $2.13. For the full year of 2023, the company expects worldwide […]
Merck (NYSE: MRK) reported sales of $16 billion for the third quarter of 2023, up 7% from the same period a year ago.
GAAP net income increased 46% to $4.7 billion, or $1.86 per share, compared to last year. Adjusted EPS rose 15% to $2.13.
For the full year of 2023, the company expects worldwide sales to be $59.7-60.2 billion and adjusted EPS to be $1.33-1.38.
